Abstract
The kidneys are highly vascularized organs that normally receive 20%–25% of the cardiac output. The arterial network of the kidney is highly specialized and is adapted to the regulatory functions of this organ. It is not unusual, therefore, to encounter functional and structural changes in the kidneys in diseases of the vasculature of any etiology. The compromise in renal function that ensues adversely affects, in turn, the course of the primary vascular disease. Conversely, the successful therapy of either the underlying vascular disease or the consequent deterioration of renal function will favorably alter the course of the other. This chapter deals only with the noninflammatory vascular diseases that compromise renal blood flow and alter renal function. The specific entities to be covered are high blood pressure, malignant hypertension, renovascular hypertension, scleroderma, embolic diseases, and renal vein thrombosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Veterans Administration Cooperative Study on Anti-hypertensive Agents: Effects of treatment on morbidity in hypertension. I. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA 202: 1028 1034, 1967.
Veterans Administration Cooperative Study on Anti-hypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90–114 mmHg. JAMA 213: 1143–1152, 1970.
Hypertension Detection and Follow-Up Cooperative Group: Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242: 2652–2671, 1979.
Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K: The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh blood pressure study. JAMA 264: 354–358, 1990.
Kaplan NM: The role of the kidney in hypertension. Hypertension 1: 456–461, 1979.
Klahr S: The kidney in hypertension: villain and victim. N Engl J Med 320: 731–733, 1989.
Zucchelli P, Zuccala A: Primary hypertension—how does it cause renal failure? Nephrol Dial Transplant 9: 223–225, 1994.
Whelton PK, Klag MJ: Hypertension as a risk factor for renal disease. Review of clinical and epidemiological evidence. Hypertension 13 (Suppl I): 19–27, 1989.
Abraham PA, Mascioli SR, Launer CA, Flack JM, Liebson PR, Svensen KH, Grandits GA, Opsahl JA, Schoenberger JA, Grimm RH: Urinary albumin and N-acetyl-ß-D- glucosaminidase excretions in mild hypertension. Am J Hypertens 7: 965–974, 1994.
Gilbert RE, Phillips P, Jerums G: Relationship between ambulatory blood pressure and albuminuria in normal subjects. Am J Hypertens 4: 959–962, 1991.
Samuelson O: Proteinuria as a prognostic factor during long-term hypertensive care. Drugs 35 (Suppl 5): 48–54, 1988.
Cerasola G, Cottone S, D’Ignoto G: Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1 (Suppl 6): S332 - S333, 1989.
Shulman NB, Ford CE, Hall D, Blaufox D, Simon D, Langford HE, Schneider KA: Prognostic value of serum creatinine on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension 13 (Suppl I): 80–93, 1989.
Hall WD: Renal issues in the management of hypertension. Am J Hypertens 6: 245S - 250S, 1993.
Eknoyan G, Suki WN: Renal consequences of antihypertensive therapy. Semin Nephrol 11: 129–137, 1991.
Ferris TF: The kidney and hypertension. Arch Intern Med 142: 1889–1895, 1982.
Suki WN: The kidney in hypertension. Contrib Nephrol 7: 290–308, 1977.
Berglund G, Andersson O, Wilhelmsen L: Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 2: 554–558, 1976.
US Renal Data System: USRDS 1993 Annual Data Report. The National Institute of Health, National Institute of Diabetes, Digestive and Kidney Disease, Bethesda, 1993.
Brunner FP, Seiwood NH: Profile of patients on renal replacement therapy in Europe and death rates due to major causes of death groups. Kidney Int 42 (Suppl 38): S4 - S15, 1992.
Lindeman RD, Tobin JD, Shock NW: Association between blood pressure and the rate of decline in renal function with age. Kidney Int 26: 861–868, 1984.
Moyer JH, Heider C, Pevey K, Ford RV: The vascular status of a heterogeneous group of patients with hypertension, with particular emphasis on renal function. Am J Med 24: 164–176, 1958.
Rostand SG, Kirk KA, Rutsky EA, Pate BA: Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 306: 1276–1279, 1982.
Zuccheli P, Zuccala A: Ischemic nephropathy in the elderly. Contrib Nephrol 105: 13–14, 1993.
Russell RP, Whelton PK: Hypertension in chronic renal failure. Clinical presentation, prognosis, pathophysiology and treatment. Am J Nephrol 3: 185–192, 1983.
Sullivan JM, Johnson JG: The management of hypertension in patients with renal insufficiency. Semin Nephrol 3: 40–51, 1983.
Lifschitz MD: Hypertension in chronic renal failure. Contemp Issues Nephrol 4: 222–246, 1981.
Glatter KA, Graves SW, Hollenberg NK, Soszynski PA, Tao QF, Frem GJ, Williams GH, Lazarus JM: Sustained volumeexpansion and [Na,K] ATPase inhibition in chronic renal failure. Am J Hypertens 7: 1016–1025, 1994.
Vertes V, Cangano JL, Berman LB, Gould A: Hypertension in end-stage renal disease Engl J Med 280: 978–980, 1969.
Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG: Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med 285: 757–762, 1971.
Zuccheli P, Santoro A, Zuccala A: Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 8: 163–168, 1988.
Davies DL, Schalekampp MA, Beevers DG, Brown JJ, Briggs JD, Lever AF, Medina AM, Morton JJ, Robertson JIS, Tree M: Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure. Lancet 1: 683–687, 1973.
Warren DJ, Ferris TF: Renin secretion in renal hypertension. Lancet 1: 149–163, 1970.
Weidmann P, Beretta-Piccoli C, Steffen F, Blumberg A, Reubi F: Hypertension in terminal renal failure. Kidney Int 9: 294–301, 1976.
Campese VM, Romoff MS, Levitan D: Autonomic nervous system dysfunction in uremia. Kidney Int 19: 246–253, 1981.
Morgenson CE: Progression of nephropathy in long-term diabetes with proteinuria and effect of initial antihypertension treatment. Scand J Clin Lab 36: 384–388, 1976.
Woods JW, Blythe WB: Management of malignant hypertension complicated by renal insufficiency. N Engl J Med 277: 57–61, 1967.
Woods JW, Blythe WB, Huffines WD: Management of malignant hypertension complicated by renal insufficiency. N Engl J Med 291: 10–14, 1974.
Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: role of blood pressure. Kidney Int 35: 670–674, 1989.
Okuda S, Onoyama K, Fujimi S, Oh Y, Nomoto K, Omae T: Influence of hypertension on the progression of experimental autologous immune complex nephritis. J Lab Clin Med 101: 461–470, 1983.
Brenner BM: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23: 647–655, 1983.
Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamic changes vs hypertrophy in experimental glomerular sclerosis. Kidney Int 35: 654–660, 1989.
Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384–394, 1990.
Diamond JR, Karnovsky MI: Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33: 917–924, 1988.
National High Blood Pressure Eduction Program: National High Blood Pressure Education Program Working Group Report on Hypertension and Chronic Renal Failure. Arch Intern Med 151: 1280–1287, 1991.
The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). October 1992.
Jacobson H, Striker GE: Report of a workshop to develop management recommendations for the prevention of progression of chronic renal disease. J Am Soc Nephrol, in press.
Rettig R: The kidney as a determinant of hypertension. Nephrol Dial Transplant 8: 1317–1318, 1993.
Rettig R, Folberth C, Strauss H, Kopf D, Waldherr R, Unger T: Role of the kidney in primary hypertension: A renal transplantation study in rats. Am J Physiol 258: F606 - F611, 1990.
Graf C, Maser-Gluth C, De Muinck Keizer W, Rettig R: Sodium retention and hypertension after kidney transplantation in rats. Hypertension 21: 724–730, 1993.
Guidi E, Bianchi G, Rivolta E, Ponticelli C, Palo FQ, Minetti L, Polli E: Hypertension in man with a kidney transplant: Role of familial versus other factors. Nephron 41: 14–21, 1985.
Freis ED: Does moderate sodium restriction lower blood pressure? Hypertension 8: 265–266, 1986.
Ram CVS, Garrett BN, Kaplan NM: Moderate sodium restriction and various diuretics in the treatment of hypertension. Effects of potassium wastage and blood pressure control. Arch Intern Med 141: 1015–1019, 1981.
Kaplan NM: Management strategies in hypertension. Contemp Issues Nephrol 4: 339–366, 1981.
Suki WN, Dawoud F, Eknoyan G, Martinez-Maldonado M: Effects of metolazone on renal function in normal man. J Pharmacol Exp Ther 180: 6–12, 1972.
Frishman WH: ß-adrenoreceptor antagonists: new drugs and new indications. N Engl J Med 305: 500–506, 1981.
The Norwegian Multi-Center Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807, 1981.
Braunwald E, Muller JE, Kloner RA, Maroko PR: Role of beta-adrenergic blockade in the therapy of patients with myocardial infarction. Am J Med 74: 113–123, 1983.
Weber MA, Drayer JIM: Renal effects of beta-adrenoreceptor-blockade. Kidney Int 18: 686–699, 1980.
Wright AD, Barber SG, Kendall MJ: Beta-adrenoreceptor blocking drugs and blood sugar control in diabetes mellitus. Br Med J 1: 159–161, 1979.
Greenblatt DJ, Koch-Wesser J: Adverse reactions to propranolol in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J 86: 478–485, 1973.
Rosa RM, Silva P, Young JB, Brown RS, Rowe JW, Epstein FH: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 302: 431–434, 1980.
Fröhlich ED: Methyldopa. Mechanism and treatment 25 years later. Arch Intern Med 140: 954–959, 1981.
Pettinger WA: Clonidine, a new antihypertensive drug. N Engl J Med 293: 1179–1180, 1975.
Saameli K, Jerie P, Scholtysik G: Guanfacine and other centrally acting drugs in antihypertensive therapy: pharmacological and clinical aspects. Clin Exp Hypertens [A] 4: 209–219, 1982.
Chidsey CA, Gottlieb TB: The pharmacological basis of antihypertensive therapy: the role of vasodilator drugs. Prog Cardiovasc Dis 17: 99–113, 1974.
Koch-Wesser J: Hydralazine. N Engl J Med 295: 61–65, 1981.
Graham RM, Pettinger WA: Prazosin. N Engl J Med 300: 232–236, 1979.
Veterans Administration Cooperative Study on Antihypertensive Agents: Comparison of prazosin with hydralazine in patients receiving hydrochlorothiazide. A randomized, double-blind clinical trial. Circulation 64: 772–779, 1981.
Keusch GW, Weidmann P, Campese V, Lee DBN, Upham AT, Massry SG: Minoxidil therapy in refractory hypertension. Analysis of 155 patients. Nephron 21: 1–15, 1979.
Mitchell JC, Graham RM, Pettinger WA: Renal function during long-term treatment of hypertension with minoxidil. Comparison of benign and malignant hypertension. Ann Intern Med 93: 676–681, 1980.
Ram CVS: Clinical application of therapeutic advances. Captopril. Arch Intern Med 142: 914–916, 1982.
Rubin B, Antonaccio MJ, Horowitz ZP: Captopril: a new orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent. Prog Cardiovasc Dis 21: 183–187, 1978.
Vidt DG, Bravo EL, Fouad FM: Captopril. N Engl J Med 306: 214–219, 1982.
Bauer JH, Reams GP, Lai SM: Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 147: 1397–1400, 1987.
Zatz R, Anderson S, Meyer TW, Dunn BR, Rennke HG, Brenner BM: Lowering arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes. Kidney Int 31 (Suppl 20): S123 - S129, 1987.
Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 73: 375–380, 1982.
Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293: 471–474, 1986.
Hommel E, Parving HH, Mathiesen E, Edsberg B, Damkjaer NM, Geise J: Effect of Captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 293: 467–170, 1986.
Parving HH, Hommel E, Schmidt UM: Protection of kidney function and decrease in albuminuria by Captopril in insulin-dependent diabetics with nephropathy. Br Med J 297: 1086–1091, 1988.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotension-converting-enzyme inhibition of diabetic nephropathy. N Engl] Med 329: 1456–1462, 1993.
Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving H-H, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus. Am J Kidney Dis 25: 107–112, 1995.
Bauer JH, Reams GP, Lai SM: Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 147: 1397–1400, 1987.
Keane WF, Anderson S, Aurell M, Zeeuw D, Narins NG, Povan G: Angiotension-converting enzyme inhibitors and progressive renal insufficiency. Ann Intern Med 111: 503–516, 1989.
Mann JFE, Reisch C, Ritz E: Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function. A retrospective study. Nephron 55 (Suppl l): 38–42, 1990.
Levenson DJ, Dzau VJ: Effects of angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis. Kidney Int 31 (Suppl 20): S173 - S179, 1987.
Mujais SK, Fouad FM, Texor SC, Tarazi RC, Bravo EL, Hart N, Gifford RW: Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J 52: 63–71, 1984.
Textor SC, Bravo E, Fouad FM: Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with Captopril. Am J Med 73: 719–725, 1982.
Ram CVS: Calcium antagonists in the treatment of hypertension. Am J Med Sei 290: 118–133, 1985.
Loutzenhizer R, Epstein M: Effects of calcium antagonists on renal hemodynamics. An editorial review. Am J Physiol 249: F616 - F621, 1985.
Chan L, Schrier RW: Effects of calcium-channel blockers on renal function. Annu Rev Med 41: 289–309, 1990.
Sunderrajan S, Reams G, Bauer JH: Long-term renal effects of diltiazem in essential hypertension. Am Heart J 114: 383–388, 1987.
Reams GP, Hamory A, Lau A, Bauer JH: Effect of nifedipine on renal function in patients with essential hypertension. Hypertension 11: 452–456, 1988.
Huthen UL, Katzman PL: Renal effects of acute and long-term treatment with felodipine in hypertension. J Hypertens 6: 231–237, 1988.
Mimran A, Insua A, Ribstein J, Momaier L, Bringer J, Mirouze J: Contrasting effects of Captopril and nifedipine in normotensive patients with diabetic nephropathy. J Hypertens 6: 919–923, 1988.
Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112: 707–708, 1990.
Brazy PC, Fitzwilliam JF: Progressive renal disease: role of race and antihypertensive medications. Kidney Int 37: 1113–1119, 1990.
Epstein M: Calcium antagonists and the kidney: implications for renal protection. Am J Hypertens 6: 251S - 259S, 1993.
Koch-Weser J: Hypertensive emergencies. N Engl J Med 290: 1367–1369, 1975.
Keith TA: Hypertension crisis. Recognition and management. JAMA 237: 1570–1577, 1977.
Carry CL: Current treatment of malignant hypertension. JAMA 232: 1367–1369, 1975.
Ram CVS: Hypertensive encephalopathy—recognition and management. Arch Intern Med 138: 1851–1853, 1978.
Bhatia SK, Fröhlich ED: Hemodynamic comparison of agents useful in hypertensive emergencies. Am Heart J 85: 367–373, 1973.
Calhoun DA, Oparil S: Treatment of hypertensive crises. N Engl J Med 323: 1177–1183, 1990.
Gifford RW: Management of hypertensive crises. JAMA 266: 829–835, 1991.
Cohn JH, Burke LP: Nitroprusside. Ann Intern Med 91: 752–757, 1979.
Ram CVS, Kaplan NM: Individual titration of diazoxide dosage in the treatment of severe hypertension. Am J Cardiol 43: 627–630, 1979.
Houston MC: Treatment of hypertensive emergencies and urgencies with oral Clonidine loading and titration. A review. Arch Intern Med 146: 586–589, 1986.
Haft JI, Litterer WE: Chewing nifedipine to rapidly treat hypertension. Arch Intern Med 144: 2357–2359, 1984.
Wilson DJ, Wallin JD, Vlachakis ND, Freis ED, Vidt DG, Michelson EL, Langford HG, Flamenbaum W, Poland MP: Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med 74: 95–102, 1983.
Brollaz J, Waeber B, Brunner HR: Hypertensive crisis treated with orally administered Captopril. Eur J Clin Pharmacol 25: 145–149, 1983.
Reams GP, Lai SM, Whalen JJ, Bauer JH: Enalaprilat—an intravenous substitute for oral enalapril therapy. J Clin Hypertens 3: 245–253, 1986.
DiPette DJ, Ferraro JC, Evans RR: Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor in hypertensive crisis. Clin Pharmacol Ther 38: 199–204, 1985.
Byron FB: The evolution of acute hypertensive arterial disease. Prog Cardiovasc Dis 17: 31–37, 1974.
MacMahon HE: Malignant nephrosclerosis—a reappraisal. Pathol Ann 3: 297–334, 1968.
Allison PR, Bleeham N, Brown W, Pickering GW, Robb- Smith AHT, Russell RP: The production and resolution of hypertensive vascular lesions in the rabbit. Clin Sei 33: 39–51, 1967.
Pickering G: Reversibility of malignant hypertension. Follow-up of three cases. Lancet 1: 413–418, 1971.
Mroczek WJ, Davidov M, Gavrilovich L, Finnerty F: The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 40: 893–904, 1969.
Lawton WJ: The short-term course of renal function in malignant hypertensives with renal insuffiency. Clin Nephrol 17: 277–283, 1982.
Friedlander MM, Rubinger D, Popovtzer MM: Improved renal function in patients with primary renal disease after control of severe hypertension. Am J Nephrol 2: 12–14, 1982.
Eknoyan G, Siegel MB: Survival from anuria due to malignant hypertension. JAMA 215: 1122–1125, 1971.
Dichoso CC, Minuth ANW, Eknoyan G: Malignant hypertension: recovery of kidney function after renal allograft failure. Arch Intern Med 135: 300–303, 1975.
Ram CVS, Hyman D: Hypertensive crisis. J Intensive Care Med 2: 151–162, 1987.
Mahoney JF, Gibson GR, Shiel AGR, Storey BG, Stokes GS, Stewart JH: Bilateral nephrectomy for malignant hypertension. Lancet 1: 1036–1038, 1972.
McCarron DA, Rubin RJ, Varnes BA, Harrington JT, Nillan EG: Therapeutic bilateral renal infarction in end-stage renal disease. N Engl J Med 294: 652, 1976.
Pettinger WA, Mitchell JC: Minoxidil. An alternative to nephrectomy for refractory hypertension. N Engl J Med 289: 167–171, 1973.
Mroczek WJ: Malignant hypertension: kidneys too good to be extirpated. Ann Intern Med 80: 754–757, 1974.
Rimmer JM, Gennari FJ: Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med 118:712— 719,1993.
Maxwell MH, Bleifer KH, Franklin SJ, Varady PO: Demographic analysis of study. JAMA 220: 1195–1209, 1972.
Simon N, Franklin SS, Bleifer KH, Maxwell MH: Characteristics of renovascular hypertension. JAMA 220: 1209–1218, 1972.
Hunt JC, Scheps SG, Harrison EG, Strong CG, Bernatz PE: Renal and renovascular hypertension. A reasoned approach to diagnosis and management. Arch Intern Med 133: 988–999, 1974.
Working Group on Renovascular Hypertension: Detection, evaluation, and treatment of renovascular hypertension. Final report. Arch Intern Med 147: 820–829, 1987.
Jacobson HR: Ischemic renal disease: an overlooked clinical entity? Kidney Int 34: 729–743, 1988.
Grim CE, Weinberger MH: Renal artery stenosis and hypertension. Semin Nephrol 3: 52–64, 1983.
Missouris CG, Buckenham T, Cappucio FP, Mac Gregor GH: Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med 96: 10–14, 1994.
Schreiber MJ, Pohl MA, Novick AC: Preserving renal function by revascularization. Annu Rev Med 41: 423–429, 1990.
Mailloux LU, Bellucci AG, Mossey RT, Napolitano B, Moore T, Wilkes BM: Predictors of survival in patients undergoing dialysis. Am J Med 84: 855–862, 1988.
Dzau VJ, Gibbons GH, Levin DC: Renovascular hypertension: an update on pathophysiology, diagnosis and treatment. Am J Nephrol 3: 172–184, 1983.
Brookstein JJ, Abrams HL, Buenger RE, Lecky J, Franklin SS, Reis MD, Bleifer KH, Klatte EC, Varady PD, Maxwell MH: Urography in unilateral renovascular disease. JAMA 220: 1225–1230, 1972.
Grim CE, Luft FC, Weinberger MH, Grim CM: Sensitivity and specificity of screening tests for renal vascular hypertension. Ann Intern Med 91: 617–622, 1979.
McNeil BJ, Varady PD, Burrows BA, Adelstein SJ: Measures of clinical efficacy: cost effectiveness calculation in the diagnosis and treatment of hypertensive renovascular disease. N Engl J Med 293: 216–221, 1975.
Hollenberg NK, Williams GH, Adams DF, Moore T, Brown C, Boruki LJ, Leung F, Bavli S, Solomon HS, Passan D, Dluhy R: Response to saralasin and angiotensin role in essential and renal hypertension. Medicine 58: 115–127, 1979.
Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN: Clinical experience with blockade of the renin-angiotensin aldosterone system by an oral converting-enzyme inhibitor (SQ14225, Captopril) in hypertensive patients. Prog Cardiovasc Dis 21: 195–206, 1978.
Staessen J, Wilms G, Baert A, Fagard R, Lynen P, Suy R, Amery A: Blood pressure during long-term convertining-enzyme inhibition predicts the curability of renovascular hypertension by angioplasty. Am J Hypertens 1: 208–214, 1988.
Navis G, de Jong PE, Donker AJM, van der Hem GK, de Zeeuw D: Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 31: 815–819, 1987.
Sealey JE, Buhler FR, Laragh JH, Vaughan D: The physiology of renin secretion in essential hypertension: estimation of renin secretion rate and renal plasma flow from peripheral and renal vein renin levels. Am J Med 55: 391–401. 1973.
Marks LS, Maxwell MH: Renal vein renin. Value and limitations in the prediction of operative results. Urol Clin North Am 2: 311–325, 1975.
Vaughan ED, Buehler FR, Laragh JH, Sealey JE, Baer L, Bard RH: Renovascular hypertension: renin measurement to indicate hypersecretion and contralateral suppression, estimate renal blood flow, and score for surgical curability. Am J Med 65:402-114,1973.
Sos TA, Pickering TG, Sniderman K, Saddekin S, Case DB, Silane MF, Vaughan ED, Laragh JH: Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. N Engl J Med 309: 274–279, 1983.
Madias NE: Renovascular hypertension. Nephrol Lett 3: 27–42, 1986.
Mann SJ, Pickering TG: Detection of renovascular hypertension. State of the art. Ann Intern Med 117: 845–853, 1992.
Davidson RA, Wilcox CS: Newer tests for the detection of renovascular disease. JAMA 268: 3353, 3358, 1992.
Martin LG, Price RB, Casarekka WJ, Stones PJ, Wells, SO, Zellmer RA, Chuang VP, Silbiger ML, Berkman WA: Percutaneous angioplasty in clinical management of renovascular hypertension: initial and long-term results. Radiology 155: 629–633, 1985.
Krener HTK, de Jong PE, de Zeeuw D, Donker AMJ, Schuur KH, van der Hem GK: Restenosis prevalence and long-term effects on renal function after percutaneous transluminal renal angioplasty. Nephrol 44 (Suppl l): 64–67, 1986.
Geyskes GG: Treatment of renovascular hypertension with percutaneous transluminal renal angioplasty. Am J Kidney Dis 12: 253–265, 1988.
Hansen KJ, Starr SM, Sands E, Burhart JM, Plonk GW, Dean R: Contemporary surgical management of renovascular disease. J Vase Surg 16: 319–331, 1992.
Buhler FR, Laragh JH, Vaughan ED, Brunner HR, Gavras H, Baer L: The antihypertensive action of propranolol. Specific anti-renin response in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 32: 511–522, 1973.
Case DB, Atlas SA, Marion RM, Laragh JH: Long-term efficacy of Captopril in renovascular and essential hypertension. Am J Cardiol 49: 1440–1446, 1982.
Aldigier JC, Ploum P, Guyene IT, Thibonnier M, Carval P, Menard J: Comparison of the hormonal and renal effects of Captopril in severe essential and renovascular hypertension. Am J Cardiol 49: 1447–1452, 1982.
Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ: Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med 308: 373–376, 1983.
Hricik DE, Dunn MJ: Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol 1: 845–858, 1990.
Jackson B, Franze L, Sumithran E, Johnson CI: Pharmacologic nephrectomy with chronic angiotensin-converting enzyme inhibitor treatment in renovascular hypertension in the rat. J Lab Clin Med 115: 21–27, 1990.
Orabona ML, Albano O: Systemic progressive sclerosis. Acta Med Scand 333 (Suppl):l-170, 1958.
Winkelmann RK: Classification and pathogenesis of scleroderma. Mayo Clin Proc 46: 83–91, 1971.
Eknoyan G, Suki WN: Renal vascular phenomena in systemic sclerosis. Semin Nephrol 5: 34–45, 1985.
Norton WL, Nardo JM: Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 73: 317–324, 1970.
Geppert T: Clinical features, pathogenic mechanisms, and new developments in the treatment of systemic sclerosis. Am J Med Sei 299: 193–209, 1990.
Medsger TA, Masi AT, Rodnan GP, Benedek TG, Robinson H: Survival with systemic sclerosis (scleroderma): a life-table analysis of demographic and clinical factors in 309 patients. Ann Intern Med 75: 369–376, 1971.
Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy C: The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 53: 1–46, 1974.
Hannigan CA, Hannigan MH, Scoh EL: Scleroderma of the kidneys. Am J Med 20: 793–797, 1956.
Rodnan GP, Schreiner GE, Black RL: Renal involvement in progressive systemic sclerosis (generalized scleroderma). Am J Med 23: 445–462, 1957.
Fisher ER, Rodnan GP: Pathologic observations concerning the kidney in progressive systemic sclerosis. Arch Pathol 65: 29–39, 1958.
Lapenas D, Rodnan GP, Cavallo T: Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma). Am J Pathol 91: 243–258, 1978.
Medsger TA, Masi AT: Survival with scleroderma-II: a life-table analysis of clinical and demographic factors in 358 males U.S. veteran patients. J Chron Dis 26: 647–660, 1973.
Richardson JA: Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis Rheum 16: 265–271, 1973.
Shapiro CB, Lerner NE, Achad AS, Abramson R, Stein RM: Malignant hypertension and uremia in scleroderma: efficacy of nephrectomy and hemodialysis. Clin Nephrol 8:321–323
Dichoso CC: The kidney in progressive systemic sclerosis (scleroderma). In: WN Suki, G Eknoyan, eds, The Kidney in Systemic Disease, 2nd ed. John Wiley & Sons, New York, pp 109–128, 1981.
Brown ST, Ahearn DJ, Nolph KD: Reduced peritoneal clearance in scleroderma increased by intraperitoneal isoproterenol. Ann Intern Med 78: 891–894, 1973.
Oliver JA, Cannon PJ: The kidney in scleroderma. Nephron 18: 141–150, 1977.
LeRoy EC, Fleischmann RM: The management of renal scleroderma: experience with dialysis, nephrectomy, and transplantation. Am J Med 64: 974–978, 1978.
Keane WF, Danielson B, Raij L: Successful renal transplantation in progressive systemic sclerosis. Ann Intern Med 85: 199–202, 1976.
Stone RA, Tisher CC, Hawkins HK, Robinson RR: Juxtaglomerular hyperplasia and hyperreninemia in progressive systemic sclerosis complicated by acute renal failure. Am J Med 56: 119–123, 1974.
Kovalchik MT, Guggenheim SJ, Silverman MH, Robertson JS, Steigerwald JC: The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 89: 881–887, 1978.
Gavras H, Gavras I, Cannon PH, Brunner HR, Laragh JH: Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? Arch Intern Med 137: 1554–1558, 1977.
Moorthy AV, Wu MJ, Bierne GJ, Sundstron WS: Control of hypertension and acute renal failure in scleroderma without nephrectomy. Lancet 1: 563–564, 1978.
Mitnich PD, Fieg PU: Control of hypertension and reversal of renal failure in scleroderma. N Engl J Med 299:871–872
Wasner C, Cooke CR, Fries JF: Successful medical treatment of scleroderma renal crisis. N Engl J Med 299: 873–875, 1978.
Lopez-Overjero JA, Saal SD, D’Angelo WA, Cheigh JS, Stenzel KH, Laragh JH: Reversal of vascular and renal crisis of scleroderma by oral angiotensin-converting enzyme blockade. N Engl J Med 300: 1417–1419, 1979.
Beckett VL, Donadio JV, Breman LA, Conn DL, Omundson PJ, Chao EYS, Holley KE: Use of Captopril as early therapy for renal scleroderma: a prospective study. Mayo Clin Proc 60: 763–771, 1985.
Whitman HH, Case, DB, Laragh JH, Christian CL, Botstein G, Maricq H, LeRoy EC: Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum 25: 241–248, 1982.
Steen VD, Costantino JP, Shapiro A, Medsger TA: Outcome of renal crisis in systemic sclerosis: relation to availability of converting enzyme (ACE) inhibitors. Ann Intern Med 113: 352–357, 1990.
Finch MB, Dawson J, Johnson GD: The peripheral vascular effects of nifedipine in Raynaud’s syndrome associated with scleroderma: a double-blind crossover study. Clin Rheumatol 5: 493–498, 1986.
Waldo R: Prazosin relieves Raynaud’s vasospasm. JAMA 241: 1037, 1979.
Winkelmann RK, Kierland RR, Perry HO, Muller SA, Sams WM: Management of scleroderma. Mayo Clin Proc 46: 128–134, 1971.
Rodnan GP: Progressive systemic sclerosis (scleroderma). In Samler, ed, Immunological Diseases, vol. II. Little, Brown, Boston, pp 1109–1141, 1978.
LeRoy EC: A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 51: 286–288, 1992.
Torres MA, Fürst DE: Treatment of generalized systemic sclerosis. Rheum Dis Clin North Am 16: 217–241, 1990.
Zachariae H, Halkier-Sorenson L, Heickendorff L, Zachariae E, Hansen HE: Cyclosporin: a treatment of systemic sclerosis. Br J Dermatol 122: 677–681, 1990.
Kahan A, Amor B, Menkes CJ, Shauch G: Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 87: 273–277, 1989.
Freundlich B, Jimenez SA, STeen VD, Medsger TA, Szkolnicki M, Jaffe HS: Treatment of systemic sclerosis with recombinant gamma interferon: a phase I/II clinical trial. Arthritis Rheum 35: 1134–1142, 1992.
Dau PC, Kahleh MB, Sagebiel RW: Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 24: 1128–1136, 1981.
Hoxie HJ, Coggin CB: Renal infarction: statistical study of 205 cases and detailed report of an unusual case. Arch Intern Med 65: 587–594, 1940.
Peterson NE, McDonald DF: Renal embolization. J Urol 100: 140–145, 1968.
Foley WJ, Kraft RO: Renal artery embolectomy. Arch Surg 103: 748–751, 1971.
Gill TJ, Dammin GJ: Paradoxical embolism with renal failure caused by occlusion of the renal arteries. Am J Med 25: 780–787, 1958.
Shabanah FH, Conolly JE, Martin DC: Acute renal artery occlusion. Surg Gynecol Obstet 131: 489–494, 1970.
Besareb A. Brown RS, Rubin NT, Salzman E, Withlin L, Steinman T, Atlia RR, Skillman JJ: Reversible renal failure following bacterial renal artery occlusive disease. Clinical features, pathology, and the role of surgical revascularization. JAMA 235: 2838–2841, 1975.
Arakawa K, Torii S, Kibuchi Y, Nakamura M: Delayed renin release in renal infarction. Arch Intern Med 129: 958–962, 1972.
Arakawa K, Torii S, Naito S, Minohara A, Vemura N, Nakamura M: Plasma renin activity as a more specific diagnostic aid for renal ’mimciion.Arch Intern Med 125: 830–834, 1970.
London IL, Hoffsten P, Perkoff GT, Pennington TG: Renal infarction. Elevation of serum and urinary lactic dehydrogenase (LDH). Arch Intern Med 121: 87–90, 1968.
Duncan DA, Dexter RN: Anuria secondary to bilateral renal-artery embolism. N Engl J Med 266: 971–973, 1962.
Smith SP, Hamburger RJ, Donohue JP, Grim CE: Occlusion of the artery to a solitary kidney. Restoration of renal function after prolonged anuria. JAMA 230:1306–1307
Kerr WK, Kyle VN, Kerestici AG, Smythe CA: Renal hypothermia. J Urol 84: 236–242, 1960.
Brest AN, Bower R, Heider C: Renal functional recovery following anuria secondary to renal artery embolism. JAMA 187: 540–542, 1964.
Perkins RP, Jacobsen DS, Feder FP, Lipchik EO, Fine PH: Return of renal function after late embolectomy. N Engl J Med 276: 1194–1195, 1967.
Millan VG, Sher MH, Deterling RA, Packard A, Morton JR, Harrington JT: Transcatheter thromboembolectomy. Arch Surg 113: 1086–1092, 1978.
Fischer CP, Konnach JW, Cho KJ, Eckhauser FE, Stanley JC: Renal artery embolism: therapy with intra-arterial streptokinase infusion. J Urol 125:402104, 1981.
Lessman RK. Johnson SF, Coburn JW, Kaufman JJ: Renal artery embolism. Clinical features and long-term follow-up of 17 cases. Ann Intern Med 89: 477–482, 1978.
Parker JM, Lord JO: Renal artery embolism. A case report with return of complete function of the involved kidney following anticoagulant therapy. J Urol 106: 339–341, 1971.
Moyer JD, Rao CN, Widrich WC, Olsson CA: Conservative management of renal artery embolus. J Urol 109: 138–143, 1973.
Flory CM: Arterial occlusions produced by emboli from eroded aortic atheromatous plaques. Am J Pathol 21: 549–565, 1945.
Retan JW, Miller RE: Microembolic complications of atherosclerosis. Literature review and report of a patient. Arch Intern Med 118: 534–545, 1966.
Tunick PA, Perez JL, Kronzon I: Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med 115: 423–427, 1991.
Kassirer JP: Atheroembolic renal disease. N Engl J Med 280: 812–818, 1969.
Smith MC, Ghose M, Henry AR: Clinical spectrum of renal cholesterol embolization. Am J Med 71: 174–180, 1981.
Fine MJ, Kapoor W, Falanga V: Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 38: 769–784, 1987.
Jones DB, Iannaccone PM: Atheromatous emboli in renal biopsies. An ultrastructural study. Am J Pathol 78:261–270
Colt HG, Begg RJ, Saporito JJ, Cooper WM, Shapiro AP: Cholesterol emboli after cardiac catheterization: eight cases and review of the literature. Medicine 67:389100, 1988.
Thurbleck WM, Castleman B: Atheromatous emboli to the kidneys after aortic surgery. N Engl J Med 257:442-177,1957.
Harrington JT, Sommers SC, Kassirer JP: Atheromatous emboli with progressive renal failure. Renal arteriography as the probably inciting factor. Ann Intern Med 68: 152–160, 1968.
Hyman BT, Landas SK, Ashman RF, Schleper RL, Robinson RA: Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 82: 1233–1237, 1987.
Bruns FJ, Segel DP, Adler S: Control of cholesterol embolization by discontinuation of anticoagulant therapy. Am J Med Sci 275: 105–108, 1978.
Handler FP: Clinical and pathological significance of atheromatous embolization with episodes of the etiology of renal hypertension. Am J Med 20: 366–373, 1956.
Richardson JH, Alderfer HH, Reid JD: Response of eye and brain to microemboli. Ann Intern Med 57: 1013–1017, 1962.
Case Records of Massachusetts General Hospital (Case 25–1967). N Engl J Med 276: 1368–1377, 1967.
Richards AM, Eliot RS, Kanjub VI, Bloemendaal RD, Edwards JE: Cholesterol embolism. A multisystem disease masquerading as polyarteritis nodosa. Am J Cardiol 15: 696–707, 1965
Levine J, Rennke HG, Idelson BA: Profound persistent eosinophilia in a patient with spontaneous renal atheroembolic disease. Am J Nephrol 12: 377–379, 1992.
Schwartz MW, McDonald GB: Cholesterol embolization syndrome: occurrence after intravenous streptokinase therapy for myocardial infarction. JAMA 258: 1934–1937, 1987
Kasinath BS: Eosinophilia as a clue to the diagnosis of atheroembolic renal disease. Arch Intern Med 147: 1384–1385, 1987.
Cosio F, Zager R, Sharma H: Atheroembolic renal disease causes hypocomplementemia. Lancet 2: 118–121, 1985.
Antonucci F, Pizzoliitlo S, Travaglini M: Atheroembolic renal disease: clinicopathologic correlations. Adv Exp Med Biol 252: 59–63, 1989.
McGowan JA, Greenberg A: Cholesterol atheroembolic renal disease: report of 3 cases with emphasis on diagnosis by skin biopsy and extended survival. Am J Nephrol 6:135–139
Anderson WR, Richards AM: Evaluation of lower extremity muscle biopsies in the diagnosis of atherembolism. Arch Pathol 86: 535–541, 1968.
Mannesse CK, Blankestijn PJ, Manin’t VAJ, Schalekamp MAD: Renal failure and cholesterol crystal embolization: a report of 4 surviving cases and a review of the literature. Clin Nephrol 36: 240–245, 1991.
Siemons L, van der Henvel P, Parizel G, Bayssens N, DeBroe MF., Cuykens JJ: Peritoneal dialysis in acute renal failure due to cholesterol embolization: two cases of recovery of renal function and extended survival. Clin Nephrol 28:205–208
Baum NH, Moriel E, Carlton CE: Renal vein thrombosis. J Urol 119: 443–148, 1978.
Harrison CV, Milne MD, Steiner RE: Clinical aspects of renal vein thrombosis. Q J Med 25: 285–298, 1956.
McCarthy LJ, Titus JL, Daugherty GW: Bilateral renal vein thrombosis and the nephrotic syndrome in adults. Ann Intern Med 58: 837–857, 1963.
Baird WL, Buchanan DP: The nephrotic syndrome following thrombosis of the inferior vena cava. Am J Med 32: 128–130, 1962.
Llach F, Arieff AI, Massry SG: Renal vein thrombosis and nephrotic syndrome. A prospective study of 36 adult patients. Ann Intern Med 83: 8–14, 1975.
Llach F, Papper S, Massry S: The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 69: 819–827. 1980.
Harrington JT, Kassirer JP: Renal vein thrombosis. Annu Rev Med 33: 255–262, 1982.
Llach F: Hypercoaguability, renal vein thromosis, and other thrombotic complications of the nephrotic syndrome. Kidney Int 28: 429–439, 1985.
Trew PA, Biava CG, Jacobs RP, Hopper J: Renal vein thrombosis in membranous glomerulonephropathy. Incidence and association. Medicine 47: 269–335, 1968.
Rosenmann E, Pollak VE, Pirani CL: Renal vein thrombosis in the adult—a clinical and pathologic study based on renal biopsies. Medicine 47: 269–335, 1968.
Huch KM, Wall BM, Cooke CR: Acute renal vein thrombosis in patients with spinal cord injury and secondary amyloidosis. Am J Med Sci 308: 119–122, 1994.
McFarland JB: Renal venous thrombosis in children. Q J Med 34: 269–290, 1965.
Arneil GC, MacDonald AM, Murphy AV, Sweet EM: Renal vein thrombosis. Clin Nephrol 1: 119–131, 1973.
Wegner GP, Crummy AB, Flaherty TT, Hipona FA: Renal vein thrombosis: a roentgenographic diagnosis. JAMA 209: 1661–1667, 1969.
Bernard DB: Extrarenal complications of the nephrotic syndrome. Kidney Int 33: 1184–1202, 1988.
Kirulata HG, Bruce AW, Jarzylo SV, Morrin PAF: The protean manifestations of renal vein thrombosis in the adult. J Urol 115: 634–638, 1976.
Kanfer A, Kleinknecht D, Broyer M, Josso F: Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh 24: 562–571, 1970.
Kendall AG, Lohmann RC, Dossetor JB: Nephrotic syndrome: a hypercoagulable state. Arch Intern Med 127:1021— 1027, 1971.
Thomson C, Forbes DC, Prentice CRM, Kennedy AC: Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med 43: 399–407, 1974.
Nachman RL, Silverstein R: Hypercoagulable states. Ann Intern Med 119: 819–827, 1993.
Love PE, Santoro SA: Antiphospholipid antibodies. Anticardiolipin and lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Arch Intern Med 112: 682–698, 1990.
Hipona FA, Crummy AB: The roentgen diagnosis of renal vein thrombosis: clinical aspects. Am J Roentgen Radiat Ther Nucl Med 93: 122–131, 1966.
Mulhern CB, Arger PH, Miller WT, Chait A: The specificity of renal vein thrombosis. Am J Roentgen Radiat Ther Nucl Med 125: 291–299, 1975.
Rosenfield AT, Zeman RK, Cronan JJ, Taylor KJW: Ultrasound in experimental and clinical renal vein thrombosis. Radiology 137: 735–741, 1980.
Zerhouni EA, Barth KH, Ziegelman SS: Demonstration of venous thrombosis by computer tomography. Am J Roentgen Radiat Ther Nucl Med 134: 753–758, 1980.
Gatewood OMB, Fishman EK, Burrow CR, Walker WG, Goldman SM, Ziegelman SS: Renal vein thrombosis in patients with nephrotic syndrome: CT diagnosis. Radiology 159: 117–122, 1986.
Tempany CM, Zerhouni EA: Clinical magnetic resonance imaging of the vascular system. Top Magn Reson Imaging 2: 13–30, 1990.
Erantantoni JD, Ness P, Simon TL: Thrombolytic therapy. Current status. N Engl J Med 293: 1073–1076, 1975.
Bromberg WD, Firlit CF: Fibrinolytic therapy for renal vein thrombosis in the child. J Urol 143: 86–88, 1990.
Kennedy JS, Gerety BM, Silverman R, Pattison ME, Siskind MS, Pond GD: Simultaneous renal arterial and venous thrombosis associated with idiopathic nephrotic syndrome: treatment with intra-arterial urokinase. Am J Med 90: 124–127, 1991.
Segasothy M, Parameswaran V: Thrombolytic therapy in a patient with chronic renal vein thrombosis. Nephron 59: 168–169, 1991.
Laville M, Aguilera D, Maillet PJ, Labeeuw M, Madona O, Zach P: The prognosis of renal vein thrombosis: a re-evaluation of 27 cases. Nephrol Dial Transplant 3: 247–256, 1988.
Hobbs DC, Twomey TM: Kinetics of polythiazide. Clin Pharmacol Ther 23: 241–246, 1978.
Beerman B, Groschinsky-Grind M: Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 12: 297–303, 1977.
Dargie HJ, Allison ME, Kennedy AC, Gray AJ: High dose metolazone in chronic renal failure. Br Med J 1: 196–198, 1972.
Tilsone WJ, Dargie HJ, Dargie EN, Morgan HG, Kennedy AC: Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther 16: 322–329, 1974.
Acchiardo SR, Skoutakis VA: Clinical efficacy, safety and pharmacokinetics of indapamide in renal impairment. Am Heart J 106: 237–244, 1983.
Beerman B, Dalen E, Linstron B: Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22: 70–78, 1977.
Rane A, Villeneuve JP, Stone WJ, Wilkenson JR, Branch RA: Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 24: 199–207, 1978.
Schwartz FD, Pillay V, Kark RM: Ethacrynic acid: its usefulness and untoward effect. Am Heart J 79: 427–428, 1970.
Davies DL, Lant AF, Millard NR, Smith AJ, Ward JW. Wilson GM: Renal action, therapeutic use and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther 15: 141–155, 1974.
Barclay JE, Lea HA: Clinical and pharmacokinetic studies of bumetanide in chronic renal failure. Postgrad Med J 51 (Suppl): 3–16, 1975.
Kramer WG, Rudy DW, Gehr TWB, Matzke GR, Sica DA, Brater DC: Torsemide pharmacokinetics and pharmacodynamics in patients with chronic renal insufficiency. In: Puschett SB, Greenberg A, eds, DIURETICS IV. Excerpta Medica, Amsterdam, pp 107–111, 1993.
Karin A: Spironolactone: disposition, metabolism, pharmacodynamics and bioavailability. Drug Metab Rev 8: 151–188, 1978.
Knaut H, Schnippenkotter I, Wais U, Geissler H, Grebian B, Mutschler E: Diuretic activity and renal elimination of triamterene and metabolites in renal insufficiency. Kidney Int 13: 528–529, 1978.
Schwartz A, Seller R, Onesti G, Kim, Swartz C, Brest AN: Pharmacodynamic effects of a new potassium-sparing diuretic, amiloride. J Clin Pharmacol 9: 217–223, 1969.
Stenbock O, Myhre E, Rugstad HE, Arnold E, Hanson T: Pharmacokinetics of methyldopa in healthy man. Eur J Clin Pharmacol 12: 117–123, 1977.
Myhre E, Brodwall EK, Stenbock O, Hanson T: Plasma turnover of methyldopa in advanced renal failure. Acta Med Scand 191: 343–347, 1972.
Yeh BK, Dayton PG, Waters WC: Removal of alpha methyldopa (Aldomet) in man by dialysis. Proc Soc Exp Biol Med 135: 840–843, 1970.
Dollery CT, David DS, Draffon GH, Dargie JH, Dean CR, Reid JL, Clare RA, Murray S: Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 19: 11–17, 1976.
Hulter HN, Licht JH, Ienicki LP, Singh S: Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency./Lab Clin Med 93: 223–231, 1979.
Stitzel RE: The biological fate of reserpine. Pharmacol Rev 28: 179–208, 1976.
Zoster IT, Johnson GE, DeVeber GA, Paul H: Excretion and metabolism of reserpine in renal failure. Clin Pharmacol Ther 14: 325–330, 1973.
Bauer JH: Effects of guanabenz therapy on renal function and body fluid composition. Arch Intern Med 143: 1163–1167, 1983.
Carchman SH, Crowe JT: Steady-state plasma levels and pharmacokinetics of guanfacine in hypertensive patients with normal renal function. Clin Pharmacol Ther 37: 186–192, 1985.
Wilkinson R: (3-blockers and renal function. Drugs 23:195–206, 1982.
Johnsson G, Regardh CG: Clinical pharmacokinetics of p-adrenoreceptor blocking drugs. Clin Pharmacokinet 1: 233–263, 1976.
Vincent J, Meredith PH, Eliott HL, Reid JL: The pharmacokinetics of doxazosin. Br J Clin Pharmacol 21: 521–524, 1986.
Reidenberg MM, Drayer D, De Marco AL, Bello CT: Hydralazine elimination in man. Clin Pharmacol Ther 14: 970–977, 1973.
Talseth T: Studies on hydralazine: elimination and steady-state concentration in patients with impaired renal function. Eur J Clin Pharmacol 10: 311–317, 1976.
Gottlieb TB, Thomas RC, Chedsey CA: Pharmacokinetic studies of minoxidil. Clin Pharmacol Ther 13: 436–441, 1972.
Lowenthal DT, Mutterperl RE, Zinns G: Bioavailability, pharmacokinetics and pharmacodynamics of minoxidil in chronic renal failure (abstract). Clin Pharmacol Ther 21: 109, 1977.
Asher JP, Murray KM: Use of angiotensin-converting-enzyme inhibitors in the management of renal disease. Clin Pharm 10: 25–31, 1991.
Rommel AJ, Pieridew AM, Heald A: Captopril elimination in chronic renal failure. Clin Pharmacol Ther 27: 282, 1980.
Todd PA, Heel RC: Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–248, 1986.
Lancaster SG, Todd PA: Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 35: 646–669, 1988.
Wadsworth AW, Brogden RN: Quinapril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 41: 378–399, 1991.
Balfour JA, Goa KL: Benazepril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 42: 511–539, 1991.
Todd PA, Benfield P: Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 39: 110–135, 1990.
Hui KK: Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 49: 457–467, 1991.
Saltiel E: Felodipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 36: 387–428, 1988.
Pederson OL, Knisell LR, Sihm I, Jespersen LT, Thomsen K: Long-term effects of isradipine on blood pressure and renal function. Am J Med 86 (Suppl 4A): 15–18, 1989.
Sorkin EM, Clissald SP: Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties. Drugs 33: 296–245, 1987.
Saruta T, Ishu M, Abe K, Iamura I: Efficacy and safety of amlodipine in hypertensive patients with renal dysfunction. Clin Cardiol 17: 317–324, 1994.
Laher MS, Kelly JG, Doyle GD: Pharmacokinetics of amlopidine in renal impairment. J Cardiovasc Pharmacol 12 (Suppl 7): S60 - S63, 1988.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Eknoyan, G. (1998). Noninflammatory Vascular Disease of the Kidney. In: Suki, W.N., Massry, S.G. (eds) Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6632-5_30
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6632-5_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-6634-9
Online ISBN: 978-1-4757-6632-5
eBook Packages: Springer Book Archive